Literature DB >> 21461444

Stability of carboplatin and oxaliplatin in their infusion solutions is due to self-association.

Anthony J Di Pasqua1, Deborah J Kerwood, Yi Shi, Jerry Goodisman, James C Dabrowiak.   

Abstract

Carboplatin and oxaliplatin are commonly used platinum anticancer agents that are sold as ready-to-use aqueous infusion solutions with shelf lives of 2 and 3 years, respectively. The observed rate constants for the hydrolysis of these drugs, however, are too large to account for their long shelf lives. We here use electrospray-trap mass spectrometry to show that carboplatin and oxaliplatin are self-associated at concentrations in their ready-to-use infusion solutions (~27 mM and 13 mM, respectively) and, as expected, when the drug concentration is reduced to more physiologically relevant concentrations (100 μM and 5 μM, respectively) the association equilibrium is shifted in favor of the monomeric forms of these drugs. Using (1)H NMR we measure the intensity of the NH resonance of the two symmetry-equivalent NH(3) molecules of carboplatin, relative to the intensity of the γ-methylene CH resonance, as a function of total drug concentration. Then, by fitting the data to models of different molecularity, we show that the association complex is a dimer with a monomer-dimer association constant of K (M(-1)) = 391 ± 127. The work presented here shows that carboplatin and oxaliplatin mainly exist as association complexes in concentrated aqueous solution, a property that accounts for the long term stability of their ready-to-use infusion solutions, and that these association complexes may exist, to some extent, in the blood after injection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21461444     DOI: 10.1039/c0dt01758b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  7 in total

Review 1.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

2.  Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

Authors:  Matthew D Hall; Katherine A Telma; Ki-Eun Chang; Tobie D Lee; James P Madigan; John R Lloyd; Ian S Goldlust; James D Hoeschele; Michael M Gottesman
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

3.  Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.

Authors:  Marek T Wlodarczyk; Sylwia A Dragulska; Olga Camacho-Vanegas; Peter R Dottino; Andrzej A Jarzęcki; John A Martignetti; Aneta J Mieszawska
Journal:  ACS Biomater Sci Eng       Date:  2018-01-09

4.  Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.

Authors:  Kimiko Ishiguro; Yong-Lian Zhu; Z Ping Lin; Philip G Penketh; Krishnamurthy Shyam; Rui Zhu; Raymond P Baumann; Alan C Sartorelli; Thomas J Rutherford; Elena S Ratner
Journal:  J Transl Sci       Date:  2016-03-05

5.  Oxaliplatin reacts with DMSO only in the presence of water.

Authors:  Hristo P Varbanov; Daniel Ortiz; Doris Höfer; Laure Menin; Mathea S Galanski; Bernhard K Keppler; Paul J Dyson
Journal:  Dalton Trans       Date:  2017-07-18       Impact factor: 4.569

6.  Cytotoxicity of Alizarine versus Tetrabromocathecol Cyclometalated Pt(II) Theranostic Agents: A Combined Experimental and Computational Investigation.

Authors:  Gloria Mazzone; Stefano Scoditti; Rossella Caligiuri; Loredana Ricciardi; Emilia Sicilia; Maria Giovanna Lupo; Isabella Rimoldi; Nicolas Godbert; Massimo La Deda; Andreea Ionescu; Mauro Ghedini; Iolinda Aiello; Giorgio Facchetti
Journal:  Inorg Chem       Date:  2022-04-25       Impact factor: 5.436

7.  Multi-spectroscopic monitoring of molecular interactions between an amino acid-functionalized ionic liquid and potential anti-Alzheimer's drugs.

Authors:  Srishti Sharma; Manoj Kumar Banjare; Namrata Singh; Jan Korábečný; Kamil Kuča; Kallol K Ghosh
Journal:  RSC Adv       Date:  2020-10-23       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.